1. Challenges in Early Cancer Drug Development Q: What are the biggest challenges you see facing early development oncology and how could you become part of the solution?…

1. POTENTIAL OF PHASE II TRIALS IN DRUG DEVELOPMENT Dr. Bhaswat S. Chakraborty Senior Vice President and Chairman, R&D Core Committee Cadila Pharmaceuticals Ltd. 5th…

Slide 1Part 2 Colorectal Cancer Thursday, July 26, 2012 7:30 PM – 8:30 PM ET RTP TV: Emerging Treatment Strategies in Colorectal Cancer Slide 2 Richard M Goldberg, MD Professor…

Slide 1www.OncologyEducation.ca Efficacy of BSI-201, a PARP-Inhibitor in combination with Gemcitabine/Carboplatin in Triple Negative Breast Cancer: Randomized Phase II trial…

Slide 1Highlights in the Management of Breast Cancer Rome, May 25-26, 2007 CLINICAL CASE Dott.ssa Jamara Giampietro Cattedra di Oncologia Medica Università G. DAnnunzio…

Slide 12002/10/02 3rd Kitasato-Harvarad Sympo Several Years Experience on Bridging Studies and the Future National Cancer Center Hospital Head, Breast and Medical Oncology…

Slide 1vervolg CASUS Slide 2 september 2009 -inmiddels 6 kuren R-CVP ondergaan -restadiering: PR EN NU? Slide 3 september 2009 -watch and wait -onderhoud rituximab -autologe…

Slide 1Setting up clinical trials in WM Prof. Dr. C. Buske EWMnetwork London 16.8.2014 Slide 2 Waldenström J Acta Medica Scandinaviva 1944 A rare disease with all implications!…

Slide 1Hyponatremia, Heart Failure, and the role of Tolvaptan (Samsca) Slide 2  Authors: John B. O’Connell, MD and Addis Alemayehu, PharmD  Funding: Heart Failure…

Folie 1 Cetuximab + Capecitabine + Irinotecan (CCI) Versus Cetuximab + Capecitabine + Oxaliplatin (CCO) as 1st-Line Therapy for Patients With Metastatic Colorectal Cancer…